Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus
Open Access
- 2 July 2026
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 92 (10) , 3622-3633
Abstract
Aims: Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and 24h ) and maximum drug concentration were comparable between paediatric patients and adults for canagliflozin 100‐ or 300‐mg QD. Simulated steady‐state AUC 24h was similar between QD and BID dosing for the same canagliflozin total daily dose in paediatric patients and adults with T2DM. QD to BID bridging was supported by simulated HbA1c and change from baseline in HbA1c in paediatric patients. Conclusions: No canagliflozin dose adjustments are required alone or in combination with metformin to ensure similar plasma exposures between paediatric and adult patients with T2DM, as well as similar HbA1c lowering between QD and BID dosing in paediatric patients.Keywords
Funding Information
- Johnson and Johnson
This publication has 10 references indexed in Scilit:
- Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta‐Analysis of Randomized Controlled TrialsPediatric Diabetes, 2024
- The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptorsBritish Journal of Pharmacology, 2023
- The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptorsBritish Journal of Pharmacology, 2023
- The Concise Guide to PHARMACOLOGY 2023/24: TransportersBritish Journal of Pharmacology, 2023
- Effect of inadequate care on diabetes complications and healthcare resource utilization during management of type 2 diabetes in the United StatesPostgraduate Medicine, 2022
- An Update on the Epidemiology of Type 2 DiabetesEndocrinology and Metabolism Clinics of North America, 2021
- Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetesPediatric Diabetes, 2017
- Dynamic population pharmacokinetic–pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice‐daily dosing of canagliflozinBritish Journal of Clinical Pharmacology, 2017
- An estimated glomerular filtration rate equation for the full age spectrumNephrology Dialysis Transplantation, 2016
- Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitusAnnals of the New York Academy of Sciences, 2015